BD announced the global commercial release of its Research Cloud 7.0, a cloud‑based platform that incorporates the Horizon Panel Maker, an AI‑powered tool that automatically generates optimized panel recommendations for immunology and cancer research experiments. The tool can produce panels in seconds by drawing on curated databases and allows researchers to compare options through detailed tables and complexity scores.
The Horizon Panel Maker is designed to integrate seamlessly with BD’s FACSDiscover Cell Analyzer and cell sorters. By automating panel design, the platform reduces experimental setup time, cuts reagent waste, and improves data quality, enabling scientists to focus on analysis rather than logistics.
BD’s AI strategy has accelerated over the past year, with earlier launches such as the Incada Connected Care Platform, Pyxis Pro, and HemoSphere Alta. The Research Cloud 7.0 extends this ecosystem by coupling AI software with BD’s hardware, creating a closed‑loop solution that can drive recurring subscription revenue and deepen customer lock‑in.
The immunology and cancer research market is projected to reach several billion dollars in the next decade, and BD estimates that the Research Cloud could capture a significant share of the AI‑enabled research platform segment. While BD claims its tool is the only commercially available solution that supports integrated imaging and spectral panel design for FACSDiscover instruments, competitors such as Thermo Fisher’s Attune and Beckman Coulter’s CytoFLEX also offer AI‑assisted panel design, creating a competitive landscape that will test BD’s differentiation.
Financially, BD reported trailing‑twelve‑month revenue of $21.84 billion, up 8.24% year‑over‑year, and guidance for FY25 adjusted diluted EPS of $14.30 to $14.60. The company did not disclose specific revenue projections for the new platform, and investors expressed caution about near‑term monetization, reflecting a focus on long‑term innovation rather than immediate earnings impact.
Steve Conly, BD Biosciences president, said the new AI tool “helps scientists reach high‑quality insights in a fraction of the time, while reducing complexity and potential for error.” He added that the platform “unlocks the full potential of our FACSDiscover Cell Analyzer and Cell Sorters, enabling researchers to get the most out of both cutting‑edge hardware and software.”
Investors reacted cautiously to the announcement, with a muted market response that underscored concerns about the platform’s short‑term revenue contribution despite its strategic importance to BD’s AI roadmap.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.